Eliem Therapeutics (ELYM) will pause all further development of ETX-155
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition
February 9, 2023 4:01 PM ESTCompany to focus on Kv7.2/3 channel opener program and development of lead candidate, ETX-123
Pausing clinical development of ETX-155 for Major Depressive Disorder (MDD) due to challenging capital environment
Implementing corporate reorganization to extend cash runway into 2027
SEATTLE and CAMBRIDGE, United Kingdom, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) (Eliem or the Company), a... More



